## **Core Concept**
Basiliximab is a monoclonal antibody used in the prevention of acute rejection in organ transplantation. It specifically targets a component of the immune system involved in the activation and proliferation of T lymphocytes. The target of basiliximab is a subunit of the interleukin-2 receptor (IL-2 receptor).

## **Why the Correct Answer is Right**
Basiliximab works by binding to the alpha subunit (CD25) of the IL-2 receptor on the surface of T cells. This binding inhibits the receptor's interaction with IL-2, a critical cytokine required for the proliferation of T cells. By blocking this interaction, basiliximab effectively reduces the activation and proliferation of T cells, which are key players in the immune response against transplanted organs. This mechanism helps in preventing acute rejection in patients who have received kidney transplants.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because basiliximab does not target tumor necrosis factor-alpha (TNF-alpha); that is the target of other biologic drugs like infliximab and adalimumab.
- **Option B:** This option is incorrect as basiliximab is not directed against CD3; a different monoclonal antibody, muromonab-CD3, targets CD3.
- **Option D:** This option is incorrect because basiliximab does not target vascular endothelial growth factor (VEGF); drugs like bevacizumab target VEGF.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that basiliximab is used specifically for the prevention of acute rejection in renal transplant patients. It is often part of an immunosuppressive regimen that may include other drugs to prevent rejection. Basiliximab's mechanism of action and its specificity for the IL-2 receptor make it a valuable agent in the management of transplant patients.

## **Correct Answer:** C. Interleukin-2 receptor.